Immunotherapy before chemo: a new hope for Triple-Negative breast cancer?

This phase 2 trial tested whether giving the immunotherapy drug atezolizumab (Tecentriq) alone for two weeks before starting standard chemotherapy could improve outcomes for people with triple-negative breast cancer. The study enrolled 442 participants and compared the two-week window approach to starting atezolizumab and chemo together from the start. The main goal was to see if the window led to a higher rate of complete cancer disappearance by the time of surgery. The trial was terminated early, so final results are not available.